Status and perspectives of acute stroke care in Europe

  • Valeria CasoEmail author
  • Diana Aguiar de Sousa
  • Urs Fischer
Letter to the Editor

Dear editor,

Based on recently published studies, the age-standardised incidence of stroke in Europe at the beginning of the twenty-first century ranged from 95 to 290/100,000 per year [1]. An East-West and North-South gradient was observed with higher incidence rates in eastern countries and lower rates in southern countries.

Within Europe, there are two ongoing realities. Specifically, while an overall decline in stroke incidence was noted in the last two decades, several Central Eastern European countries are still experiencing increasing rates in stroke incidence and stroke-related mortality [1]. The organisational models adopted at local and national levels may be influencing these differing stroke care performances [1]; however, there are considerable variations in the quality of care for stroke patients in Europe, both between and within countries.

To this regard, in 2016, the ESO (European Stroke Organisation), European Society of Minimally Invasive Neurological Therapy...


Compliance with ethical standards

Conflicts of interests

Dr. Fischer is a Consultant for Medtronic, Stryker and Commonwealth Serum Laboratories Behring. He is a principal investigator of the SWITCH (Swiss Trial of Decompressive Craniectomy Versus Best.

Medical Treatment of Spontaneous Supratentorial Intracerebral Hemorrhage (SWITCH): A Randomised Controlled Trial), ELAN (Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients With Atrial Fibrillation: An International Multicenter, Randomised-Controlled, Two-Arm, Assessor-Blinded Trial), and SWIFT DIRECT trial (Solitaire With the Intention for Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire Stent-Retriever Thrombectomy in Acute Anterior Circulation Stroke).

Dr. Caso receives Advisory board fee for Respect-ESUS. All fees and speaker fees for Bayer, Boehringer Ingelheim, BMS-Pfizer, Ever-Neuropharma are paid to ARS UMBRIA.


  1. 1.
    Béjot Y, Bailly H, Durier J, Giroud M (2016) Epidemiology of stroke in Europe and trends for the 21st century. Presse Med 45:45.391–45e398. CrossRefGoogle Scholar
  2. 2.
    Aguiar de Sousa D, von Martial R, Abilleira S, Gattringer T, Kobayashi A, Gallofré M, Fazekas F, Szikora I, Feigin V, Caso V, Fischer; on behalf of the ESO ESMINT EAN SAFE Survey on Stroke Care Collaborators (2018) Access to and delivery of acute ischaemic stroke treatments: a survey of national scientific societies and stroke experts in 44 European countries. Eur Stroke J.
  3. 3.
    Kilbourne AM, Switzer G, Hyman K, Crowley-Matoka M, Fine MJ (2006) Advancing health disparities research within the health care system: a conceptual framework. Am J Public Health 96(12):2113–2121. CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Waje-Andreassen U, Nabavi DG, Engelter ST, DWJ D, Jenkinson D, Skoda O, Zini A, Orken DN, Staikov I, Lyrer (2018) European Stroke Organisation certification of stroke units and stroke centres. ESJ 0(0):1–7. CrossRefGoogle Scholar
  5. 5.
    Norrving, B, Barrick J, Davalos A, Dichgans M, Cordonnier C, Guekht A, Kutluk K, Mikulik R, Wardlaw J, Richard E, Nabavi D, Molina C, Bath PM, Stibrant Sunnerhagen K, Rudd A, Drummond A, Planas A, Caso V (2018) Action Plan for Stroke in Europe 2018–2030. ESJ 3(4):309–336.

Copyright information

© Fondazione Società Italiana di Neurologia 2018

Authors and Affiliations

  1. 1.Stroke Unit, Santa Maria della Misericordia HospitalUniversity of PerugiaPerugiaItaly
  2. 2.Department of Neurology, Hospital de Santa MariaUniversity of LisbonLisbonPortugal
  3. 3.Department of Neurology, University Hospital Bern, InselspitalUniversity of BernBernSwitzerland

Personalised recommendations